HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees [Yahoo! Finance]
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress [Yahoo! Finance]
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.